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Introduction
Historically, primary immunodeficiencies (PIDs) were defined by 
increased susceptibility to infections. However, it is increasingly 
recognized that immune dysregulation, inflammation, and auto-
Patients with mutations of the recombination-activating genes (RAG) present with diverse clinical phenotypes, including 
severe combined immune deficiency (SCID), autoimmunity, and inflammation. However, the incidence and extent of immune 
dysregulation in RAG-dependent immunodeficiency have not been studied in detail. Here, we have demonstrated that patients 
with hypomorphic RAG mutations, especially those with delayed-onset combined immune deficiency and granulomatous/
autoimmune manifestations (CID-G/AI), produce a broad spectrum of autoantibodies. Neutralizing anti–IFN-α or anti–IFN-ω 
antibodies were present at detectable levels in patients with CID-G/AI who had a history of severe viral infections. As this 
autoantibody profile is not observed in a wide range of other primary immunodeficiencies, we hypothesized that recurrent or 
chronic viral infections may precipitate or aggravate immune dysregulation in RAG-deficient hosts. We repeatedly challenged 
Rag1S723C/S723C mice, which serve as a model of leaky SCID, with agonists of the virus-recognizing receptors TLR3/MDA5, 
TLR7/-8, and TLR9 and found that this treatment elicits autoantibody production. Altogether, our data demonstrate that 
immune dysregulation is an integral aspect of RAG-associated immunodeficiency and indicate that environmental triggers 
may modulate the phenotypic expression of autoimmune manifestations.
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litis, psoriasis). Furthermore, 7 of 13 CID-G/AI patients (54%) 
had granulomas affecting various organs: skin, tongue, adenoids, 
spleen, lungs, and the perineal area. Most of the CID-G/AI patients 
(10 of 13, 77%) received replacement therapy with i.v. Igs (IVIGs). 
Eight patients (61.5%) received hematopoietic cell transplantation 
(HCT) at ages ranging from 1.5 to 19 years. Five CID-G/AI patients 
(38.5%) died at 5, 9, 10, 20, and 27 years of age, respectively. The 
causes of death included central line Candida sepsis (patient CID-8) 
(9); sepsis (patient CID-11); fatal Aspergillus pneumonia (patient 
CID-17) (17); graft-versus-host disease (GVHD) (patient CID-4); 
and accident after successful HCT (patient CID-1) (10). Two 
patients (CID-9 and -14) remain clinically stable on IVIGs and 
immune modulation at 30 and 17 years of age, respectively.
Among the 5 patients with LS (age range: 3 months to 18 
years; median: 2 years), 4 had a history of autoimmunity, 
including cytopenias, alopecia, vitiligo, psoriasis, and Crohn 
disease (Supplemental Table 1). All 5 had a history of infec-
tions. In particular, 3 patients experienced chronic or severe 
CMV or adenovirus infection that, in 2 of these patients (LS-5 
and LS-6), was associated with expansion of TCRγδ+ T cells. All 
patients required IVIGs, and 4 (80%) received HCT.
Among the 7 patients with OS (age range: 3 weeks to 28 
months; median: 4 months), 4 had a history of severe or recurrent 
bacterial, viral, or fungal infections (Supplemental Table 1). One 
patient (OS-11) experienced disseminated adenovirus infection. 
One patient (OS-10) developed autoimmune hemolytic anemia 
(AIHA). All OS patients received HCT at ages ranging from 2 to 
21 months; 5 of these patients are alive, and 2 patients (OS-2 and 
OS-10) died from GVHD.
Four patients had SCID, and 1 of these patients (SCID-5) had 
OS-like manifestations due to maternal T lymphocyte engraft-
ment. Two of these patients presented with severe infections 
due to respiratory syncytial virus (RSV) and Pneumocystis jiroveci, 
respectively. All SCID patients received HCT between 2 weeks 
and 4 months of age. Three are alive, whereas 1 patient (SCID-5) 
died of veno-occlusive disease (VOD) secondary to busulfan tox-
icity (Supplemental Table 1),
The characteristics of each group of patients are summa-
rized in Table 1. Functional analysis of the mutated RAG pro-
teins showed that patients with CID-G/AI carried mutations that 
allowed higher levels of residual recombination activity than did 
those identified in patients with LS, OS, or SCID (Supplemental 
Table 1), confirming our recent observations (18).
Identification of multiple autoantibodies in RAG-deficient 
patients with PID. In an attempt to characterize autoantibody 
profiles in patients with RAG deficiency and to identify the most 
common autoantigens, we probed microarrays (generated by the 
Genomic and Microarray Core Facility at the University of Texas 
Southwestern Medical Center) containing a series of autoanti-
gens involved in connective tissue diseases (Supplemental Table 
2) with plasma from 22 patients with RAG deficiency (CID-G/AI, 
n = 8; TCL, n = 1; OS, n = 7; LS, n = 2; SCID, n = 4) (Table 1 and 
Supplemental Table 1). All patients were tested for the presence 
of autoantibodies of the IgG isotype, and all but 1 (CID-9) were 
tested for autoantibodies of the IgM isotype. Fifteen of the twen-
ty-two patients (68%) were on Ig replacement therapy when the 
sample was obtained.
immunity in particular are frequently observed in patients with PID 
(1–3). Deficiency of recombinase-activating genes 1 and 2 (RAG1/2) 
is a prototypic PID with a broad phenotypic spectrum including 
susceptibility to severe infections and immune dysregulation. The 
RAG1 and RAG2 proteins initiate the V(D)J recombination process, 
enabling expression of T and B lymphocyte antigen receptors and 
thereby promoting differentiation of T and B lymphocytes. Accord-
ingly, functionally null RAG1/2 mutations hamper the development 
of T and B lymphocytes, causing T–B– severe combined immune 
deficiency (SCID) (4). By contrast, hypomorphic RAG mutations 
that allow residual expression and function of the mutant protein, 
enabling partial T and B lymphocyte development, may cause a 
spectrum of phenotypes with prominent immune dysregulation, as 
observed in patients with Omenn syndrome (OS) (5), leaky SCID 
(LS) with a predominance of T cell receptor (TCR) γδ+ T cells (6, 7), 
and combined immunodeficiency with granulomatous disease and/
or autoimmunity (CID-G/AI) (8). In the latter group of patients, 
granulomatous lesions and autoimmunity may cause systemic dis-
ease or severe organ damage, which often dominates the clinical 
picture (8–13). Furthermore, 1 patient with CD4 T cell lymphopenia 
(TCL) associated with RAG mutations has been reported (14).
We and others have reported increased levels of autoanti-
bodies in patients and in mouse models of RAG deficiency (15, 
16). However, the frequency, diversity, and pathogenicity of 
autoantibodies in patients with RAG deficiency and the potential 
role of environmental factors in triggering autoimmunity in this 
condition remain to be elucidated.
Here, we report a comprehensive analysis of autoantibody 
specificities in patients with RAG deficiency and the correla-
tion of these specificities with various clinical phenotypes. We 
demonstrate that patients with CID-G/AI in particular produce 
a broad spectrum of autoantibodies, including neutralizing anti–
IFN-α or –IFN-ω antibodies, in association with a previous history 
of severe viral infections. Chronic engagement of TLR3/MDA5, 
TLR7/-8, and TLR9 precipitated the production of autoantibod-
ies in a mouse model of LS caused by Rag1 mutations. We propose 
that viral triggers are important in promoting autoantibody pro-
duction in patients and mice with partially impaired RAG activity 
and that anti-cytokine antibodies may serve as a biomarker of an 
underlying primary immune dysfunction in these patients.
Results
Characteristics of RAG-deficient patients. We have studied 30 
patients with RAG deficiency, including 13 patients with CID-G/AI; 
5 with LS; 7 with OS; 4 with SCID; and 1 with TCL. The clini-
cal, immunological, and molecular features of these patients are 
reported in Supplemental Table 1; supplemental material avail-
able online with this article; doi:10.1172/JCI80477DS1.
Among the 13 patients with CID-G/AI (age range: 1–30 years; 
median: 10 years), the majority (11 of 13, 85%) were females. All 
had a history of infections, including severe varicella infection, 
leading to significant complications (periorbital cellulitis, hep-
atitis, encephalitis, or disseminated disease) in 6 patients (CID 
patients 2, 3, 4, 6, 9, and 13) (46%). One patient (CID-5) developed 
EBV-associated tonsillar lymphoma. Ten of the thirteen patients 
(77%) with CID-G/AI had a history of cytopenias and/or other 
autoimmune manifestations (vitiligo, myasthenia gravis, vascu-
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Distinctive anti-cytokine autoantibody signature in patients with 
RAG-dependent immunodeficiencies. Anti-cytokine antibodies 
have been detected in various PIDs and may contribute to dis-
ease phenotypes when capable of neutralizing cytokine biologi-
cal activity (19, 20). We have previously reported on the presence 
of anti–IFN-α autoantibodies in 2 siblings with RAG deficiency 
who presented with autoimmunity and immunodeficiency (21). 
However, the frequency, specificity, and biological activity of 
anti-cytokine antibodies in patients with RAG mutations and var-
ious clinical phenotypes have not been described. To address this 
issue, we probed an extended protein microarray (generated in Dr. 
Utz’s laboratory at Stanford University) containing purified cytok-
ines and chemokines (n = 63) as well as conventional autoantigens 
(n = 93) (Supplemental Table 4) with plasma from 16 healthy con-
trols and 14 RAG-deficient patients (CID-G/AI, n = 8; TCL, n = 1; 
OS, n = 3; LS, n = 2) (Table 1). A distinct panel of autoantibodies 
(cluster 2) emerged that targeted IFN-α, IFN-ω, and IL-12, mainly 
in the CID-G/AI, TCL, and LS subgroups (Figure 2A and Supple-
mental Figure 4). Significance analysis of microarrays (SAM) iden-
tified significant differences in the presence of antibodies against 
IFN-α and thyroperoxidase (TPO) in the RAG-dependent PIDs 
compared with that seen in controls (Figure 2B).
For further validation and characterization, a larger set of 
plasma samples from 23 patients with RAG mutations (CID-G/AI, 
n = 11; TCL, n = 1; OS, n = 5; LS, n = 3; SCID, n = 3) and from 
15 healthy controls was tested for the presence of anti-cytokine 
antibodies using multiplex bead technology (Supplemental 
Table 5). Among the 25 distinct target cytokines tested, anti-
bodies against IFN-α and IFN-ω were present in the majority of 
In each case, individual microarrays were also probed with 
sera from healthy donors as negative controls (n = 19 and n = 16 
for IgG and IgM autoantibodies, respectively) and from a patient 
with systemic lupus erythematosus (SLE), who lacked RAG muta-
tions, as a positive control. Both IgG and IgM autoantibodies were 
detected with increased frequency in patients with OS and in those 
with CID-G/AI (Supplemental Figures 1 and 2, respectively). We 
defined a group of RAG-deficient patients as “multireactive” 
when their plasma contained IgG autoantibodies against at least 
approximately 20% (13 of 66) of the self-antigens represented 
on the array. The relative frequency of multireactive samples 
was higher in RAG-deficient patients than in healthy controls 
(P = 0.0000008) and was especially high in patients with a 
milder phenotype (CID-G/AI and TCL) compared with sam-
ples in patients with a more severe presentation (SCID/LS/OS) 
(P = 0.028) (Figure 1A). However, multireactive autoantibodies 
were also detected in 1 patient with OS (OS-5) and in the sin-
gle patient with SCID and maternal engraftment (SCID-5). We 
identified 21 common autoantigens, defined as specific tar-
gets for IgG autoantibodies that were present in at least 20% 
of the patients studied (Supplemental Figure 3). Among these, 
11 autoantigens were detected at significantly higher levels in 
multireactive patients belonging to the CID-G/AI subgroup as 
compared with the levels detected in healthy controls (P < 0.05) 
(Supplemental Table 3). These autoantibodies included some 
that are characteristic of various autoimmune diseases such as 
SLE, rheumatoid arthritis, and Sjögren’s syndrome (Ro/SSA-
52Kda, U1-snRNP-BB’, proteoglycan, alanyl-tRNA synthetase), 
and celiac disease (tissue transglutaminase [tTG]) (Figure 1B).
Figure 1. Autoantibodies in RAG-deficient patients as detected by protein microarray. (A) IgG autoantibodies in 19 healthy controls (HCs) and 22 
patients with RAG mutations. RAG-deficient patients were divided into 2 groups according to the severity of the clinical phenotype. Group 1 included 
patients with T–B– SCID, OS, and LS. Group 2 included patients with delayed presentation and/or a milder phenotype: CID-G/AI and TCL. MFI was nor-
malized to that of healthy controls (mean + 2 SDs = 1), generating the RAR. Healthy controls had a lower percentage of positivity than did patients 
with RAG mutations (P = 0.0000008), and group 1 had a lower percentage of positivity than did group 2 (P = 0.028) as determined by Wilcoxon test 
with Holm’s adjustment. Samples that reacted to at least 20% of the self-antigens were defined as multireactive. (B) RAR to 11 autoantigens for 
which significantly higher levels of autoantibodies were found in the plasma of 5 CID-G/AI patients as compared with levels in 19 healthy controls. 
*P < 0.0005, **P < 0.0001, and ***P < 0.0001 by Wilcoxon test with Holm’s adjustment. Empty boxes indicate the range of RAR in healthy controls, 
with the bar representing the mean value. Hemo, hemocyanin; MPO, myeloperoxidase; PCNA, proliferating cell nuclear antigen; PL-12, alanyl-tRNA 
synthetase; PG, proteoglycan; RPLP, ribosomal phosphoprotein 0; Ro/SSA, ribonucleoprotein/Sjögren’s syndrome antigen A, 52 kDa; Tg, thyroglobulin; 
U1-BB’, U1 small nuclear ribonucleoprotein BB’ 9; U1-C, U1 small nuclear ribonucleoprotein C.
Downloaded from http://www.jci.org on October 27, 2015.   http://dx.doi.org/10.1172/JCI80477
The Journal of Clinical Investigation R e s e a R c h  a R t i c l e
4 jci.org
deficiency and a CID-G/AI phenotype (n = 8) and in 1 patient with 
OS (Supplemental Figure 6).
To assess whether a similar pattern of anti-cytokine antibod-
ies may also be observed in other PIDs, we applied multiplex bead 
technology to study the presence of anti-cytokine antibodies in 
the plasma of patients with partial DiGeorge syndrome (n = 19), 
chronic granulomatous disease (CGD) (n = 7), and other PIDs 
(common variable immunodeficiency [CVID], n = 8; polysaccha-
ride antibody deficiency, n = 3; ataxia-telangiectasia, n = 3). IgG 
autoantibodies targeting granulocyte CSF (G-CSF) and IFN-γ 
were detected in 3 patients with partial DiGeorge syndrome, and 
TNF-α and IFN-γ antibodies were detected in 2 patients with 
CGD. One patient with ataxia-telangiectasia had a combination of 
anti–IFN-α and anti–IFN-ω antibodies. In summary, patients with 
a PID other than RAG deficiency are also found to have anti-cytok-
ine antibodies — but not to the degree found in patients with RAG 
mutations — and with a different signature of antigen specificity.
Finally, we searched for IgM antibodies against various cytok-
ines (IFN-α, IFN-ω, IL-17, and IL-22) in plasma from 4 CID-G/AI 
patients (CID-2, -3, -9, and -12); 2 LS patients (LS-6 and -7); and 1 OS 
(OS-11) patient, all of whom had tested positive for IFN-α and/or 
IFN-ω IgG antibodies. Only low levels of IgM autoantibodies were 
detected, comparable to what we observed in healthy controls 
(n = 9) (data not shown).
In summary, anti-cytokine antibodies were analyzed by 1 or 
more of 3 methods (autoantigen protein microarray, multiplex bead 
assay, ELISA) in plasma from 23 patients with RAG mutations, 15 of 
whom had also been tested for conventional autoantibodies. The 
patients with CID-G/AI (7 of 11, 63.6%), TCL (1/1), and LS (2 of 3, 
66%), but were less frequently detected in patients with OS 
(1 of 5, 20%) and SCID (1 of 3, 33.3%). By contrast, none of the 
15 healthy controls had detectable antibodies against IFN-α or 
IFN-ω. In addition, antibodies targeting IL-12, IL-22, TNF-α, 
IFN-γ, and IL-6 were seen in a minority of patients (Figure 2C). 
Of note, the anti–TNF-α autoantibodies detected in patients 
CID-12 and CID-14 likely reflected prior treatment with inflix-
imab, a chimeric monoclonal antibody against TNF-α. Of the 2 
patients with anti–IFN-γ antibodies, CID-12 had chronic myco-
bacterial infection prior to HCT. Most of the anti-cytokine anti-
bodies detected were of the IgG1 isotype (data not shown). None 
of the patients had antibodies against BAFF as determined by the 
extended protein microarray (generated in Dr. Utz’s laboratory 
at Stanford University) (Supplemental Table 4).
The presence of anti–IFN-α, –IFN-ω, and –IL-12 antibodies 
was further validated by ELISA in a subgroup of 18 RAG-deficient 
patients from whom samples were available for testing (CID-G/AI, 
n = 9; TCL, n = 1; OS, n = 3; LS, n = 3; SCID, n = 2; Figure 2D and 
Table 1), and the correlation with the results of autoantibody test-
ing by multiplex bead assay is shown in Supplemental Figure 5.
To investigate whether use of IVIG may contribute to increased 
levels of anti-cytokine antibodies in RAG-deficient patients on 
Ig replacement therapy, we used ELISA to analyze anti–IFN-α, 
anti–IFN-ω, and anti–IL-12 antibody levels in 5 IVIG preparations 
diluted to a final concentration of 600 mg/dl IgG. Significantly 
lower levels of anti-cytokine antibodies were detected in the IVIG 
preparations as compared with serum levels in patients with RAG 
Table 1. Patient and sample characteristics
Phenotype CID-G/AI TCL LS OS SCID
No. of pts. 13 1 5 7 4
F/M sex ratio 11 F/2 M 1 F 2 F/3 M 4 F/3 M 2 F/2 M
Age range for Ab testing 1–30 yr 18 yr 5 d–13 yr 5 wk–2.5 yr 1–20 mo
Pts. with clinical autoimmune man. (%) 10 (77%) 0% 4 (80%) 2 (28.5%) 0%
Pts. with granulomas (%) 7 (54%) 0% 0% 0% 0%
Pts. with infections (%) 13 (100%) 1 (100%) 5 (100%) 4 (57%) 2 (50%)
Pts. with severe viral infections 6 (43%) 1 (100%) 3 (60%) 1 (14%) 1 (25%)
Viruses causing severe infections VZV VZV CMV, adenovirus Adenovirus RSV
Pts. treated with HCT 8 (61.5%) 0 (0%) 4 (80%) 7 (100%) 4 (100%)
Age range of HCT-treated pts. 1.5–19 yr – 18 mo–18 yr 2–21 mo 2 wk–4 mo
Overall survival 8 (61.5%) 1 (100%) 5 (100%) 5 (71%) 3 (75%)
Cause of death Sepsis (2), GVHD (1), 
Aspergillus pneumonia (1), 
accident (1)
– – GVHD (2) VOD (1)
Subjects tested for IgG auto-Abs  
(n = 22)
5/8 (62%) 0/1 0/2 1/7 (14%) 1/4 (25%)
Subjects tested for anti–IFN-α and/or IFN-ω Abs
Microarray (n = 14) 5/8 (62%) 1/1 2/2 (100%) 1/3 (33%) –
Multiplex bead assay (n = 23) 7/11 (63.6%) 1/1 2/3 (66%) 1/5 (20%) 1/3 (33%)
ELISA (n = 18) 5/9 (56%) 1/1 2/3 (66%) 1/3 (33%) 0/2
Subjects with anti–IFN-α–neut. Abs 6/6 (100%) 1/1 2/2 (100%) 1/1 (100%) 0/1
Subjects with anti–IFN-ω–neut. Abs 5/5 (100%) 1/1 2/2 (100%) 0/1 (100%) –
F, female; M, male; man., manifestations; neut., neutralizing; pts., patients. 
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their neutralizing activity in a subset of patients for whom we had 
sufficient plasma available. We assessed the ability of plasma from 
healthy donors or from RAG-deficient patients containing anti-
cytokine autoantibodies to prevent either phosphorylation of the 
STAT molecules STAT1, -3, and -4 upon stimulation of peripheral 
results consistently identified a distinctive signature of IgG anti-
cytokine antibodies, especially in patients with CID-G/AI.
Anti-cytokine antibodies in patients with RAG-dependent immu-
nodeficiencies have neutralizing activity. To study the possible bio-
logical role of the anti-cytokine antibodies detected, we evaluated 
Figure 2. Anti-cytokine antibodies in 
RAG-deficient patients. (A) Heatmap of 
autoantibody reactivity. Plasma samples 
from 16 healthy controls (Ctr), 14 RAG-de-
ficient patients (OS, n = 3; LS, n = 2; CID-G/
AI, n = 8; idiopathic CD4+ TCL, n = 1), and 
1 patient with APS-1 were tested for anti-
cytokine antibodies. The complete array is 
shown in the left panel, and the area with 
the highest reactivity is magnified on the 
right. Antibodies against IFN-α, IFN-ω, 
and IL-12 (in red) were detected with high 
MFI in cluster 2, including RAG-deficient 
patients and APS-1 patients as a positive 
control. (B) Elevated levels of antibodies 
against TPO and IFN-α were detected in 
RAG-deficient patients as compared with 
healthy controls using SAM after 10,000 
permutations of the data with an FDR 
of less than 0.00001. (C) Multiplex bead 
assay for anti-cytokine antibodies. Levels 
of antibodies targeting IFN-α, IFN-ω, 
IL-12p70, IFN-γ, IFN-β, TNF-α, and IL-22 in 
healthy controls (n = 15) and RAG-deficient 
patients (n = 23), grouped by phenotype: 
SCID, n = 3; LS, n = 3; OS, n = 5; CID-G/
AI, n = 11; and TCL, n = 1. (D) Detection 
of anti–IFN-α-2A, –IFN-ω, and –IL-12p70 
antibodies by ELISA. Plasma samples 
were assayed for IgG autoantibodies at a 
200-fold dilution. RAG-deficient patients 
included those with SCID (n = 2); LS (n = 3); 
OS (n = 3); CID-G/AI (n = 9); and TCL (n = 1). 
In both C and D, floating bars indicate the 
range of values for each autoantibody in 
healthy controls (n = 15 in C; n = 6 in D).
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blood mononuclear cells (PBMCs) with the appropriate cytokines 
(IFN-α, IFN-ω, IFN-γ, IL-22, and IL-12), or induction of thymocyte 
antigen 1 (Thy1) surface expression in Jurkat 3T8 cells upon stim-
ulation with TNF-α. Data on the presence and neutralizing activ-
ity of anti-cytokine antibodies are summarized in Supplemental 
Table 6, and representative panels are shown in Figure 3, A–D, for 
each anti-cytokine antibody tested.
In particular, except for patient SCID-3 with a low titer of 
anti–IFN-α antibodies, all other plasma samples containing 
anti–IFN-α autoantibodies (6 of 6 CID-G/AI, 1 of 1 TCL, 2 of 2 
LS, and 1 of 1 OS) inhibited IFN-α–induced STAT1 phosphory-
lation (Figure 3A and Supplemental Table 6). Similarly, all but 1 
of the samples containing anti–IFN-ω antibodies (5 of 5 CID-G/
AI, 1 of 1 TCL, 2 of 2 LS, and 0 of 1 OS) blocked IFN-ω–induced 
STAT1 phosphorylation (Figure 3A and Supplemental Table 6). In 
3 patients with anti–IL-12 antibodies (2 patients with CID-G/AI 
and 1 patient with TCL), plasma from patient CID-1 completely 
prevented IL-12–induced STAT4 phosphorylation (Figure 3B), 
while samples from the patient with TCL and from patient CID-
9 were partially neutralizing or failed to neutralize IL-12, respec-
tively (Supplemental Table 6). Anti–IL-22 autoantibodies were 
detected in 2 patients; in the case of patient CID-1, anti–IL-22 
antibodies were fully neutralizing (Figure 3C), whereas patient 
LS-7 had anti–IL-22 antibodies at low titers, and their neutralizing 
activity could not be tested. The anti–TNF-α antibodies detected 
in 2 patients with CID-G/AI were neutralizing as determined by 
TNF-α–induced Thy1 surface expression in Jurkat 3T8 cells (Fig-
ure 3D). Finally, the anti–IFN-γ antibodies detected in patients 
CID-12 and OS-5 did not demonstrate neutralizing activity as 
determined by the STAT1 phosphorylation assay (Supplemental 
Table 6). These results show that the anti-cytokine antibodies 
were antagonistic and could substantially reduce signaling via 
engagement of the respective cytokine receptors.
Anti-cytokine antibodies are associated with severe viral infections 
in patients with RAG-dependent immunodeficiencies. To investigate 
possible triggers of anti–IFN-α/ω antibodies, we searched the 
medical records for relevant clinical commonalities and found that 
4 of the 6 patients with CID-G/AI (patients CID-2, -3, -9, and -13) 
and the single patient with TCL with neutralizing anti–IFN-α/ω 
antibodies had a history of severe varicella. Furthermore, both 
patients with LS and neutralizing anti–IFN-α antibodies (LS-6 
and LS-7) had histories of CMV infection, and 1 patient (LS-7) also 
experienced adenovirus infection, which had also been recorded 
in the single patient with OS (OS-11) with anti–IFN-α/ω antibod-
ies (Table 1 and Supplemental Table 1). Of note, in patients TCL-1 
and CID-9, anti-cytokine antibodies persisted for many years 
Figure 3. Neutralizing activity of anti-cytokine antibodies. (A) Neutralizing activity of anti–IFN-α, anti–IFN-γ, and anti–IFN-ω antibodies. Normal PBMCs 
were incubated in the presence of plasma from a healthy control (left panel) or from a RAG-deficient patient (right panel), and left unstimulated or stim-
ulated with either IFN-α, IFN-γ, or IFN-ω. STAT1 phosphorylation was measured by flow cytometry. The neutralizing effect of plasma from patient CID-12 
on IFN-α (red), and IFN-ω (green), but not on IFN-γ (blue), is shown as a representative example. (B) Neutralizing activity of anti–IL-12p70 antibodies. 
Normal lymphoblasts were incubated in the presence of plasma from a healthy control (left panel) or from RAG-deficient patient CID-1 as a representative 
example (right panel) and left unstimulated or stimulated with IL-12p70. STAT4 phosphorylation was measured by flow cytometry. (C) Neutralizing activity 
of anti–IL-22 autoantibodies. A549 adenocarcinomic human alveolar basal epithelial cells were incubated in the presence of plasma from a healthy control 
(left panel) or from RAG-deficient patient CID-1 as a representative example (right panel) and left unstimulated or stimulated with IL-22. STAT3 phospho-
rylation was measured by flow cytometry. (D) Neutralizing activity of anti–TNF-α antibodies. Jurkat 3T8 cells were incubated in the presence of plasma 
from a healthy control (left panel) or from RAG-deficient patient CID-12 as a representative example (right panel) and left unstimulated or stimulated with 
TNF-α overnight. Thy1 surface expression was measured by flow cytometry.
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after complicated varicella infection (Supplemental Table 1). 
In summary, the majority of subjects with significant levels of 
anti-cytokine antibodies had a history of severe viral infections. 
In order to determine whether severe varicella infection alone 
could be associated with the presence of anti-cytokine antibod-
ies, regardless of RAG deficiency, we tested plasma samples from 
5 patients with a previous history of severe varicella infection 
and a lack of obvious immunodeficiency (n = 1) or the presence 
of other, non–RAG-dependent, forms of PID (n = 4), including 2 
patients with ORAI1 deficiency, 1 patient with DOCK2 deficiency, 
and 1 patient with SCID with an unknown genetic defect. None 
of these patients had detectable levels of anti-cytokine antibod-
ies. This result suggests that a history of varicella infection alone 
is not sufficient to elicit anti-cytokine antibodies in patients with 
immunodeficiencies other than RAG deficiency.
Repeated TLR3/MDA5 stimulation increases autoantibody 
production in a mouse model of LS due to Rag1 mutation. The 
occurrence of autoimmune cytopenias has been previously 
reported in patients with LS due to RAG mutations and CMV 
infection (6, 7), and our new data confirm that autoantibodies 
(including anti-cytokine antibodies) are more commonly 
detected in patients with RAG mutations with a history of viral 
infections. Previous work in mice has shown that high-dose 
administration of poly(I:C), a ligand for TLR3/MDA5 that mim-
ics viral infection, results in increased innate immune responses 
in multiple models of immune deficiency (22). Furthermore, 
TLR3/MDA5, TLR7/-8, or TLR9 engagement converts T lym-
phocyte autoreactivity into overt autoimmune disease in a 
T lymphocyte–dependent murine model of diabetes (23). On 
the basis of these observations, we tested the hypothesis that 
repeated stimulation of TLR viral sensors may trigger autoan-
tibody production in a mouse model with hypomorphic Rag 
mutations. We injected low doses of TLR3, TLR7/-8, and TLR9 
agonists (or PBS as a negative control) i.p. weekly for 12 weeks 
into 6- to 8-week-old mice with a homozygous Rag1 S723C muta-
tion (mut/mut mice, a model of LS) (15, 24) and their wild-type 
(WT) littermates. After the 12-week period of weekly injections, 
the mice were tested for the presence of autoantibodies in the 
plasma using a microarray similar to that used to analyze the 
presence of autoantibodies in patients. As shown in Figure 4A, 
a subset of mut/mut mice (8 of 15, 53.3%) produced autoanti-
bodies even at baseline, confirming previous data of immune 
dysregulation in this model of LS (15, 16). Within 12 weeks after 
the initiation of weekly injections of TLR3/MDA5, TLR7/-8, and 
TLR9 agonists, an increase in the frequency and spectrum of 
IgM and IgG autoantibodies produced was observed in mut/mut 
mice compared with WT mice (Figure 4, A and B). A trend 
toward higher levels of autoantibodies against various anti-
gens, including single-stranded DNA (ssDNA), double-stranded 
DNA (dsDNA), chromatin, histone, and Ro/SSA, was observed 
in poly(I:C)-treated mut/mut mice as demonstrated by higher 
signal intensity (Supplemental Figure 7, A and B). In compari-
son, autoantibody polyreactivity was not observed at baseline or 
after treatment with PBS in WT mice. Some autoantibody pro-
duction was observed upon injection of CpG or R848 into WT 
mice, but only 1 of 5 (20%) sera samples from poly(I:C)-treated 
WT mice showed polyreactivity (Figure 4B). Increased levels 
of dsDNA and ssDNA autoantibodies in mut/mut mice at base-
line, and even more so after repeated poly(I:C) injection, were 
confirmed by ELISA (Figure 4C and Supplemental Figure 8). 
The kinetics of anti-ssDNA and -dsDNA autoantibody produc-
tion in mut/mut mice at intermediate time points (weeks 4 and 8) 
after initiation of TLR/MDA5 agonist injection is shown in Sup-
plemental Figure 9. Anti-cytokine antibodies targeting IFN-α, 
IFN-ω, or IL-12 were not detected by ELISA in any of the mice, 
either spontaneously or after injection of TLR agonists (data not 
shown). In summary, these results demonstrate that repeated 
triggering of innate viral sensors (and TLR3/MDA5 in partic-
ular) elicits and/or increases multiple autoantibody levels in 
Rag-mutated mice but not in controls.
Discussion
The present report, to the best of our knowledge, involves the larg-
est cohort of patients with the CID-G/AI phenotype and RAG defi-
ciency described to date. Consistent with our recent observations 
(18), this group of patients carried mutations that allowed higher 
residual recombination activity when compared with other RAG- 
deficient patients, suggesting that the functional activity of the 
mutant RAG protein may affect the clinical phenotype. Interestingly, 
there was a marked predominance (85%) of female individuals 
among the patients with CID-G/AI, whereas no sex predominance 
was observed in patients with LS, OS, or SCID phenotypes. Four 
additional patients with RAG deficiency and the CID-G/AI pheno-
type have been reported recently, 3 of whom were males (12, 25, 26). 
Even if these cases were included, a female preponderance (70%) 
would nonetheless be observed among patients with CID-G/AI. 
A predominance of female patients has been reported in several 
forms of autoimmune disease in the general population (27–31). 
Therefore, it is possible that besides the nature of the mutation, sex 
may also affect the risk of developing CID-G/AI in patients with 
RAG deficiency. Although patients with the CID-G/AI phenotype 
often survive to adulthood, even without HCT, a high proportion of 
the patients in our cohort eventually died due to sudden infections 
or transplant complications, with a low overall survival rate of 60%.
Using 3 different platforms, we have demonstrated that 
patients with RAG deficiency, and especially those with 
CID-G/AI, produce a broad spectrum of autoantibodies. 
Increased autoantibody production in patients with hypomor-
phic RAG mutations may reflect impairment of both central and 
peripheral B cell tolerance (15, 16). In particular, reexpression of 
the RAG proteins during B cell development is essential to trigger 
further V(D)J recombination and receptor editing, thus reducing 
the proportion of immature B cells with self-reactive specificity 
that are released from the bone marrow (BM) (32–34). This mech-
anism is compromised in patients and mice with RAG mutations 
(15, 16). Furthermore, impairment of B cell development in RAG 
deficiency is associated with increased serum levels of BAFF, 
which may promote survival of self-reactive immature B cells 
(15, 16). Interestingly, none of the patients included in this study 
showed evidence of anti-BAFF antibodies, which represented a 
cardinal feature in a recent study of patients with SLE (35).
We have demonstrated that patients with hypomorphic RAG 
mutations have a distinctive signature of anti-cytokine antibodies, 
particularly those against IFN-α, IFN-ω, and IL-12. This profile 
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While B and T cell tolerance defects are directly related to 
RAG deficiency, environmental factors may also play an impor-
tant role in modifying the disease phenotype and aggravating or 
precipitating autoimmunity in patients with hypomorphic RAG 
mutations. In particular, we have identified a clear association 
between the presence of neutralizing anti–IFN-α, anti-IFN-ω, and 
anti–IL-12 antibodies and a history of severe viral infections, such 
as those caused by varicella zoster virus (VZV), CMV, and aden-
ovirus. Of note, these anti-cytokine antibodies were produced in 
patients at a young age following severe viral infection and tended 
to persist for several years.
Activation of innate viral sensors may play an important 
role in modifying the disease phenotype in RAG-deficient hosts. 
Enhanced production of proinflammatory cytokines has been pre-
viously reported when PBMCs from a patient with CID-G/AI were 
activated in vitro with phytohemagglutinin (PHA) and poly(I:C) 
(10). The observation that repeated injections of TLR3/MDA5, 
TLR7/-8, and TLR9 agonists in mice promotes the production of 
a broad range of autoantibodies is consistent with the hypothesis 
that persistent viral infections and sustained induction of proin-
flammatory responses may trigger or aggravate autoimmunity in 
genetically susceptible hosts. Chronic elevations of IFN-α levels 
have been implicated in the development of autoimmune disease 
in humans, including type I diabetes, scleroderma, and lupus (52). 
Furthermore, anti–IFN-α antibodies have also been demonstrated 
in patients with malignancies who received IFN-α treatment (53), 
in patients with myasthenia gravis or thymoma (36, 54, 55), and 
in an otherwise healthy subject with dermatomal varicella zoster 
reactivation that progressed to disseminated infection (56).
The neutralizing nature of most of the anti–IFN-α and anti–
IFN-ω antibodies detected in patients with CID-G/AI suggests 
that these cytokine-specific autoantibodies could have impor-
tant biological and clinical relevance. In particular, we propose 
that viral infections induce a highly inflammatory milieu with 
increased production of IFN-α and IFN-ω in the absence of proper 
adaptive regulatory mechanisms. In the setting of impaired tol-
erance, neutralizing autoantibodies are generated, which may in 
some cases counteract elevated IFN levels. These neutralizing 
autoantibodies may dampen the inflammatory response but also 
further compromise antiviral immune responses, predisposing to 
infection-related complications.
Treatment of mut/mut mice with various TLR agonists 
enhanced the production of autoantibodies against a wide 
range of self-antigens, and this effect was especially promi-
nent for poly(I:C), which is both a TLR3 and MDA5 agonist and 
triggers IFN-α production in all tissues. However, injection of 
has been confirmed by 3 independent platforms (microarray, 
multiplex bead assay, and ELISA) and has not been identified in 
patients with other forms of PID analyzed herein. On the other 
hand, anti–IFN-α, anti–IFN-ω, and anti–IL-12 antibodies have 
been previously reported in patients with autoimmune polyglan-
dular syndrome type 1 (APS-1) (19, 36) and thymoma (19, 36, 37). 
APS-1 is a monogenic autoimmune disorder caused by mutations 
of the gene encoding the autoimmune regulator (AIRE), a tran-
scription factor that is expressed by mature medullary thymic 
epithelial cells (mTECs) and allows expression of tissue-specific 
peptides that are presented by thymic epithelial cells and DCs to 
developing thymocytes, thereby permitting negative selection of 
self-reactive T cells (38). Impaired expression of AIRE has been 
also reported in the thymus of patients with thymoma (39–41). 
Interestingly, we have previously demonstrated profound abnor-
malities of thymic architecture, mTEC differentiation, and AIRE 
expression in patients with RAG deficiency (42, 43). The identi-
fication of a similar anti-cytokine antibody signature in patients 
with primary (APS-1) and secondary (thymoma and RAG muta-
tions) deficiencies of thymic AIRE expression strongly suggests 
that impairment of central T cell tolerance plays a critical role in 
promoting the production of a restricted pattern of anti-cytokine 
antibodies in these conditions. On the other hand, unlike patients 
with APS-1, RAG-deficient patients did not develop anti–IL-17 
antibodies. Consistent with this, candidiasis was not a common 
feature in the RAG-deficient patients described here, whereas it is 
a cardinal feature of APS-1 (18).
Circulating anti–IFN-α antibodies have been reported in 
autoimmune conditions, in SLE in particular (44–47), and even 
in healthy individuals, albeit at low frequency (37, 48–50). Fur-
thermore, pharmaceutical Ig preparations may contain variable 
amounts of neutralizing anti-cytokine antibodies, including those 
targeting IFN-α (51). While most of the RAG-deficient patients 
studied were on Ig replacement therapy, significantly lower lev-
els of anti–IFN-α, anti–IFN-ω, and anti–IL-12 antibodies were 
detected in various lots of IVIG preparations as compared with 
those found in serum from RAG-deficient patients (P = 0.0004, 
P = 0.00067, and P = 0.0043, respectively) (Supplemental Figure 
6). Moreover, anti-cytokine antibodies were also detected in 2 
patients with RAG mutations who were not on IVIG replacement 
therapy. Finally, no anti-cytokine antibodies were detected in the 
serum of 8 patients with CVID, all of whom were on IVIG therapy.
Taken together, our data indicate that hypomorphic RAG 
mutations are associated with an increased risk of producing a 
characteristic profile of anti-cytokine antibodies, particularly 
those against IFN-α and IFN-ω.
Figure 4. Autoantibody reactivity in Rag1S723C/S723C (mut/mut) mice after stimulation with TLR3/MDA5, TLR7/-8, and TLR9 agonists. (A) Detection of IgG 
autoantibodies by protein microarray. Six- to eight-week-old mut/mut and WT/WT mice received a weekly i.p. injection of either PBS, low-dose poly(I:C), 
R848, or CpG. The presence of IgG antibodies against self-antigens in plasma samples was determined at day 0 and week 12 of treatment. Plasma pooled 
from lupus-prone NZM/MRL mice served as a positive control. Scale bars represent the MFI fold increase (blue to yellow) of autoantibody reactivity as 
compared with the mean + 2 SDs of the MFI in samples from WT/WT mice. (B) Frequency of autoantibodies in mut/mut mice after TLR/MDA5 stimula-
tion. Multireactive samples were defined as containing autoantibodies against greater than or equal to 20% of 76 self-antigens. Wilcoxon test with Holm’s 
correction was used to compare results in WT/WT and mut/mut mice at baseline (week 0) and for each of the treatments and approached significance 
at week 0 (P = 0.0101). When comparing each of the 4 treatments with week 0 separately in WT/WT and in mut/mut mice, only CpG in WT/WT mice was 
significantly different (P = 0.0036). (C) Validation of dsDNA antibodies by ELISA. Plasma samples were diluted 200-fold. Wilcoxon test with Holm’s cor-
rection was used to compare results in WT/WT and mut/mut mice at baseline (week 0) and for each of the treatments as well as to compare each of the 4 
treatments with week 0 separately in WT/WT and mut/mut mice. Results from 3 separate experiments were pooled.
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Cy3-labeled anti-human IgG and Cy5-labeled anti-human IgM were 
used to detect autoantibodies. In the mouse experiments, a plasma 
pool with broad-spectrum autoantibody specificity was generated 
by mixing plasma samples obtained from aged NZM2410 and MRL/
lupus-prone (MRL/lpr) mice and used as a positive control. Cy3- 
labeled anti-mouse IgG and Cy5-labeled anti-mouse IgM antibod-
ies were used for the detection of autoantibodies. Tiff images were 
generated using a GenePix 4000B scanner (Molecular Devices) with 
laser wavelengths of 532 (for Cy3) and 635 (for Cy5) and analyzed 
using GenePix Pro 6.0 software (Molecular Devices) to generate a 
GenePix result (GPR) file. Net fluorescence intensities (NFI), defined 
as the spot minus background fluorescence intensity obtained from 
duplicate spots, were averaged. A signal-to-noise ratio (SNR) was 
used as a quantitative measure of the ability to resolve the true signal 
from background noise, and an SNR equal to or greater than 3 was 
considered a true signal in contrast to the background signal. IgG- or 
IgM-positive controls across all samples were averaged, and a positive 
control in each sample was divided by the averaged positive control, 
generating a normalization factor (NF) for each sample. For normal-
ization, each signal value was multiplied by the NF of each sample. 
As plasma samples were measured in multiple batches, a secondary 
normalization step was implemented using the negative control val-
ues represented on each array. Values from the negative control sam-
ples (at least 3 per array) were averaged for each antigen, and ratios 
between each sample (including negative control samples) and the 
average of negative controls plus 2 SDs were calculated to generate 
relative autoantibody reactivity (RAR). These data were visualized 
by Multiple Experiment Viewer (MeV), version 3 (DFCI) (59) and 
further analyzed for multireactivity and common autoantigens. The 
cutoff for production of a positive autoantibody (penetrance) against 
a particular self-antigen was defined as RAR equal to or higher than 
1. Multireactive patients were identified as patients producing auto-
antibodies against at least 20% (13 of 66) of the self-antigens repre-
sented on the microarray. Common autoantigens were determined as 
self-antigens against which IgG autoantibodies were produced in at 
least 20% of the patients with RAG deficiency.
Cytokine, chemokine, and protein autoantibody microarrays. Protein 
microarrays (generated in Dr. Utz’s laboratory at Stanford University) 
were generated using a VersArray ChipWriter Pro microarrayer (Bio-
Rad) with a customized printhead and Silicon Microarray Spotting 
Pins (Parallel Synthesis Technologies) as previously described (60). 
Briefly, 341 purified biomolecules including autoantigens, cytokines, 
and chemokines were purchased from multiple vendors and printed 
in triplicate at dilutions of 200 μg/ml onto Nexterion E epoxysilane–
coated glass slides (SCHOTT; catalog 1064016). A complete list of the 
molecules printed is provided in Supplemental Table 4. Arrays were 
first blocked in 7% FBS (Omega Scientific Inc.; catalog FB-11) in PBS 
(Sigma-Aldrich; catalog P4244) plus 0.1% Tween (Sigma-Aldrich; cat-
alog P2287) (PBST) for 1 hour at 4°C rocking and then washed 3 times 
in PBST. Arrays were probed for 1 hour with plasma diluted 1:150 in 
30% FBS in 1% PBST, with rocking at 4°C. Arrays were subjected to 
three 5-minute washes in 1% PBST. Plasma reactivity was detected 
using an Alexa Fluor 647–conjugated goat anti-human IgG secondary 
antibody (Jackson ImmunoResearch Laboratories Inc.; catalog 109-
605-044) diluted to 2.5 μg/ml in 30% FCS in 1% PBST for 45 minutes. 
Arrays were washed 3 times in PBST and dried under negative pres-
sure. Arrays were scanned using an Agilent microarray scanner and 
TLR and MDA5 agonists into mut/mut mice failed to induce 
the anti-cytokine antibody signature observed in patients with 
RAG mutations. It should be noted that mut/mut mice carry a 
rather severe Rag1 mutation and represent a model of LS, and 
not of CID-G/AI. Because the anti-cytokine antibody signature 
was predominantly observed in patients with CID-G/AI, it is 
possible that development of an anti-cytokine antibody signa-
ture in vivo requires higher residual recombination activity of 
the mutant RAG protein in order to sustain the generation of 
a sufficient number of T and B lymphocytes. To formally test 
this hypothesis, new mouse models are needed that have Rag 
mutations corresponding to those identified in patients with 
CID-G/AI and that are capable of supporting higher levels of 
recombination activity. In conclusion, we have characterized 
the autoantibody signature of patients with RAG deficiency and 
various clinical phenotypes and confirmed that immune dysreg-
ulation is a cardinal feature of this condition. A distinct profile 
of neutralizing anti-cytokine antibodies has been identified 
in patients with CID-G/AI and a history of severe viral infec-
tions and may represent a novel biomarker of this condition. 
Chronic stimulation of viral sensors with TLR3/MDA5 agonists 
enhanced autoimmunity in a mouse model of RAG deficiency, 
supporting the notion that environmental factors, besides RAG- 
dependent defects of central and peripheral tolerance, are 
involved in determining the degree of immune dysregulation 
associated with RAG deficiency.
Methods
Patients. Plasma samples were obtained at diagnosis, before 
treatment with HCT, from patients with molecularly confirmed 
RAG-dependent immunodeficiency and from age-matched con-
trols. Plasma samples from patients with RAG-nondependent PIDs 
(partial DiGeorge syndrome, idiopathic TCL, ataxia-telangiectasia, 
CVID) were also obtained.
SCID, LS, and OS were defined according to criteria from the 
Primary Immune Deficiency Treatment Consortium (PIDTC) 
(57). The CID-G/AI phenotype was defined by a clinical history 
of recurrent infections and immune dysregulation (autoimmunity 
and/or granulomas).
Mouse strains. 129Sv Rag1S723C/S723C (mut/mut) mice were previously 
described (24). 129Sv WT (+/+) mice were purchased from Charles 
River Laboratories. Mice were housed at the Karp Family Research 
Center (Boston Children’s Hospital, Boston, Massachusetts, USA) 
under specific pathogen–free conditions.
Autoantigen protein microarrays. Human and mouse IgG and IgM 
autoantibodies were measured on an autoantigen proteomic array 
(Genomic and Microarray Core Facility, University of Texas South-
western Medical Center, Dallas, Texas, USA) (58). Autoantibodies 
against a selection of self-antigens were determined, and their levels 
were visualized as heatmaps. Specifically, the human panel included 
66 and 70 self-antigens for IgG and IgM, respectively. Seventy-six 
self-antigens were used for mouse autoantibody testing (Supple-
mental Table 2). Plasma (1 μl) from patients and controls was diluted 
1:100 and added to the arrays in duplicate. In the human study, each 
microarray was also probed with plasma derived from healthy con-
trol subjects (at least 3 per array) and plasma samples from a patient 
with systemic lupus erythematous (1 per array) as a positive control. 
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BSA, washed, and then incubated with 1:200 dilutions of plasma sam-
ples from patients or controls for 2 hours at room temperature. Plates 
were thoroughly washed and then incubated with HRP-conjugated 
Fc-specific polyclonal goat anti-human IgG antibody (Pierce; catalog 
31414) for 1 hour at room temperature. After washing, HRP substrate 
was added (TMB; eBioscience; catalog 00-4202-56), and the reaction 
was terminated with sulfuric acid (Sigma-Aldrich; catalog 38294) and 
OD measured at 450 nm in an ELISA reader. Anti-cytokine autoanti-
body levels in RAG-deficient patients were compared with nonauto-
immune controls using the Mann-Whitney U test.
To test for the presence of anti-cytokine antibodies in IVIG, 
5 Ig preparations (Gammagard, lot LEIM3MAB, Baxter Health-
care; and Gamunex, lots 26NLTC1, 26NNKW3, A1GC40062, and 
A4GE400131, Grifols) were diluted in PBS to a final IgG concentration 
of 600 mg/dl and analyzed by ELISA as described above.
Analysis of neutralizing activity of anti-cytokine antibodies. Anal-
ysis of the neutralizing activity of antibodies against IFN-α, IFN-ω, 
and IFN-γ was performed by assessing STAT1 phosphorylation in 
cells stimulated with the respective cytokines, in the presence of 
plasma from patients or controls (10%) (37, 62). Briefly, PBMCs 
(5 × 105 cells/ml) were cultured in complete media consisting of 
RPMI 1640, 2 mM glutamine, 20 mM HEPES (N-2-hydroxyethyl-
piperazine-N-2-ethanesulfonic acid), 100 U/ml penicillin, 100 g/ml 
streptomycin with plasma from normal subjects or from patients 
(10%) and left unstimulated or stimulated with IFN-α (1,000 U/ml), 
IFN-ω (10 ng/ml), or IFN-γ (1,000 U/ml) for 15 minutes at 37°C. Cells 
were fixed, permeabilized, and stained with phosphorylated STAT1 
(p-STAT1) antibody (pY701; BD Pharmingen; catalog 612597).
To evaluate the neutralizing activity of anti–IL-12 autoantibod-
ies, normal PBMCs were cultured for 48 hours in complete RPMI 
with 10% FCS and 1% PHA, washed, and cultured for 24 hours with 
IL-2 (1,000 U/ml, eBioscience; catalog 34-8029), then deprived of 
serum overnight to generate IL-12–expressing lymphoblasts. The 
blasts were washed and resuspended in complete RPMI with plasma 
from normal subjects or patients (10%) and either left unstimulated 
or stimulated with IL-12 (100 ng/ml) or IFN-α (1,000 U/ml) for 15 
minutes. Cells were fixed and permeabilized as described above and 
incubated with anti–p-STAT4 antibody (pY693; BD Pharmingen; 
catalog 558137) at 4°C for 30 minutes.
Analysis of the neutralizing activity of anti–IL-22 antibodies was 
performed using A549 cells (5 × 105/ml) cultured in complete RPMI 
with plasma from normal subjects or patients (10%) that was left 
unstimulated or stimulated with IL-22 (100 ng/ml) for 30 minutes 
at 37°C. Cells were fixed, permeabilized, and stained with anti–p-
STAT3 (pY705; BD Pharmingen; catalog 557815) antibody. The assay 
was developed on the basis of observations detailed in a method 
reported by Liang et al. (63). Data were collected using FACSCali-
bur (BD Biosciences) and analyzed using FlowJo software, version 
9.7. For analysis of the neutralizing activity of anti–TNF-α antibodies, 
induction of Thy1 expression was analyzed in Jurkat 3T8 cells stimu-
lated with TNF-α (64). Briefly, Jurkat 3T8 cells (5 × 105/ml) were cul-
tured in RPMI 1640 medium containing 20 mM HEPES, 100 U/ml 
penicillin, 100 g/ml streptomycin, 1 mM sodium pyruvate, 0.1 mM 
MEM nonessential amino acids solution, and 0.5 mg/ml G418 selec-
tive antibiotic in the presence of plasma from normal subjects or 
patients (10%) and either stimulated with TNF-α (10 ng/ml) or not 
(unstimulated control) overnight at 37°C. Cells were washed and 
bioinformatically processed using GenePix Pro 6 software (Molecular 
Devices). For a selected group of patients with a documented presence 
of IgG anti-cytokine antibodies, we also examined the level of serum 
IgM antibodies relative to multiple anti-cytokine antibodies (IFN-α, 
IFN-ω, IL-22, and IL-17) by using the above-mentioned array, except 
that plasma reactivity was detected using a Cy3-conjugated goat 
anti-human IgM secondary antibody (Jackson ImmunoResearch Lab-
oratories Inc.; catalog 109-165-003) diluted to 1 μg/ml in 30% FCS in 
1% PBST for 45 minutes.
To analyze the cytokine microarray study results, mean fluores-
cence intensities (MFIs) were calculated across multiple replicates, 
and from these values were subtracted the MFI of the corresponding 
features probed with a secondary antibody alone to obtain final MFI 
values. Unsupervised hierarchical clustering of final MFI values was 
performed using Pearson’s correlation with average linkage cluster-
ing using the MeV program (59). SAM was performed as previously 
described (61).
Anti-cytokine autoantibody determination by multiplex bead assay. 
Plasma samples were screened for 23 anti-cytokine antibodies using a 
particle-based approach. Briefly, differentially fluorescing magnetic 
beads (Bio-Rad; catalogs MC1-0026-01, MC1-0027-01, MC1-0028-
01, MC1-0029-01, MC1-0034-01, MC1-0035-01, MC1-0036-01, 
MC1-0037-01, MC1-0043-01, MC1-0044-01, MC1-0045-01, 
MC1-0046-01, MC1-0052-01, MC1-0053-01, MC1-0054-01, MC1-
0055-01, MC1-0062-01, MC1-0063-01, MC1-0064-01, and MC1-
0065-01) were covalently coupled to 2.5 μg recombinant human 
IFN-α (PBL Biomedical Laboratories; catalog 11101-2); IFN-β (Pepro-
Tech; catalog 300-02BC); IFN-γ (R&D Systems; catalog 285-IF-100/
CF); IFN-λ1 (eBioscience; catalog 34-8299); IFN-λ2 (eBioscience; 
catalog 34-8289); IFN-λ3 (R&D Systems; catalog 5259-IL-025/CF); 
IFN-ω (PeproTech; catalog 300-02J); IL-1α (eBioscience; catalog 
34-8019); IL-4 (eBioscience; catalog 34-8049); IL-6 (eBioscience; 
catalog 34-8069); IL-7 (eBioscience; catalog 34-8079); IL-10 (eBio-
science; catalog 34-8109); IL-12p70 (R&D Systems; catalog 219- 
IL-005/CF); IL-15 (eBioscience; catalog 34-8159); IL-17A (R&D Sys-
tems; catalog 317-ILB-050); IL-17F (eBioscience; catalog 34-8479); 
IL-18 (R&D Systems; catalog B003-5); IL-22 (eBioscience; catalog 
34-8229); IP-10 (eBioscience; catalog 34-8967); G-CSF (eBiosci-
ence; catalog 34-8523); GM-CSF (R&D Systems; catalog 215-GM-
050/CF); M-CSF (PeproTech; catalog 300-25); TNF-α (eBioscience; 
catalog 34-8329); or TNF-β (PeproTech; catalog 300-01B). Beads 
were combined and incubated with plasma samples at a 1:100 dilu-
tion for 30 minutes, washed, then incubated with PE-labeled goat 
anti-human IgG (eBioscience; catalog 12-4998) for an additional 30 
minutes before being run in a multiplex assay on the Bio-Plex X200 
instrument (Bio-Rad). Ig subclasses were determined in a similar 
manner using biotinylated mouse anti-human IgG1, IgG2, IgG3, and 
IgG4 antibodies (Sigma Aldrich; catalogs B6775, B3398, B3523, and 
B3648, respectively) revealed by streptavidin-phycoerythrin (Bio-
Rad; catalog 171-304501).
Anti-cytokine autoantibody detection by ELISA. Ninety-six-well 
ELISA plates (MaxiSorp; Thermo Fisher Scientific; catalog 442404) 
were coated with 1 μg/ml recombinant human IFN-α, (Thermo Fisher 
Scientific; catalog BTCYT-204); IFN-ω (Thermo Fisher Scientific; cat-
alog BMS304); or IL-12p70 (BioLegend; catalog 573004) by incuba-
tion overnight at 4°C. Plates were then washed in PBS-Tween 0.05%, 
blocked by incubation with the same buffer supplemented with 2% 
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4, B and C (and Supplemental Figure 8), the assays were run on speci-
mens left over from other assays, and baseline (time = 0) and week 12 
(after treatment) specimens were most often not available. Therefore, 
we could not use longitudinal methods or paired methods, but had to 
use 2-group methods (which have less power and hence would be less 
likely to be significant than longitudinal or paired methods). GraphPad 
Prism 6.0 (GraphPad Software) was used for data analysis in Figure 
2 and Supplemental Figure 3 and for data presentation in all figures. 
For the autoantibody microarray, unsupervised hierarchical cluster-
ing was performed using Pearson’s correlation with average linkage 
clustering in the MeV program(59). SAM was performed as previously 
described, with significantly different reactivities defined by an FDR 
of less than 0.1% after 10,000 permutations of the data (61).
Study approval. Human studies were approved by the IRBs of 
Children’s Hospital Boston (protocol 04–09-113R) and Massachusetts 
General Hospital (protocol 2011-P002918). Samples from patients at 
all collaborating sites were obtained after written informed consent 
was provided by the participants or their guardians under local IRB–
approved protocols and shared as deidentified specimens for secondary 
use. Plasma samples from patients with RAG-nondependent PIDs (par-
tial DiGeorge syndrome, idiopathic TCL, ataxia-telangiectasia, CVID) 
were obtained according to protocols approved by the IRBs of Stanford 
University and Children’s Hospital of Philadelphia and according to 
Declaration of Helsinki principles.
Animal studies were approved by the IACUC of Boston Children’s 
Hospital (protocol 07–10-1445).
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stained with mouse anti-rat Thy1 antibody (BD Pharmingen; catalog 
561409), and data were collected using FACSCalibur (BD Biosci-
ences) and analyzed with FlowJo software, version 9.7.
Analysis of autoantibody production in mut/mut mice upon challenge 
with TLR/MDA5 agonists. Six- to eight-week-old WT and Rag1S723C/S723C 
(mut/mut) mice were injected i.p. weekly for 12 weeks with either 50 
μg poly(I:C) (InvivoGen; catalog TLR-PIC); 12.5 μg CpG (ODN1826; 
InvivoGen; catalog TLR-MODN); or 5 μg R848 (InvivoGen; catalog 
TLRL-R848); or with PBS. Blood was collected on day zero (baseline) 
and after 12 weeks of weekly injections, and the presence of autoan-
tibodies in the plasma was assessed by autoantibody microarray (as 
described above). Anti-ssDNA and anti-dsDNA antibodies were also 
analyzed by ELISA as previously described, with some modifications 
(65). In brief, 96-well ELISA plates (MaxiSorp; Thermo Fisher Scien-
tific; catalog 442404) were UV irradiated and then coated with 2.5 
μg/ml ssDNA (Sigma-Aldrich; catalog D8899) or 2 μg/ml dsDNA 
(Sigma-Aldrich; catalog D4522). Samples were incubated on plates 
at a 1:600 dilution. Autoantibodies were detected by ELISA, as 
described for the detection of anti-cytokine autoantibodies, using 
HRP-conjugated Fc-specific polyclonal goat anti-mouse IgG antibody 
(Pierce; catalog 31414). Anti-dsDNA and anti-ssDNA antibody levels 
were expressed as arbitrary ELISA units using a standard curve pre-
pared with serial dilutions of an NZM/MRL plasma pool with broad- 
spectrum autoantibody specificity generated from sera from aged 
NZM2410 and MRL/lpr mice. Results are expressed as the OD ratio 
(experimental OD/background OD).
Accession numbers. Protein microarray data generated by our Stan-
ford University collaborators (Jacob Rosenberg and Paul J. Utz) (Fig-
ure 2A and Supplemental Figure 4) are available in the NCBI’s Gene 
Expression Omnibus (GEO) database (GEO GSE70618) (66, 67). We 
elected to add our data generated at the Genomic and Microarray Core 
Facility of the University of Texas Southwestern Medical Center as 
supplemental data (Supplemental Table 7 for human and Supplemen-
tal Table 8 for mouse data). These data were provided as a normalized 
data set by the core facility.
Statistics. Two-sided tests were used for all statistical analyses. 
Since the various outcome measures had very different variances for 
the various groups of patients (and for the groups of mice that were 
repeatedly challenged) and since the distributions did not seem to 
be Gaussian, we used nonparametric methods: the exact Wilcoxon 
rank-sum test to compare 2 groups and the exact Kruskal-Wallis test 
to compare more than 2 groups; calculations of these tests were done 
in StatXact. P values were considered significant on the basis of the 
Holm’s adjustment for multiple comparisons (68). For K comparisons, 
the smallest P value is compared with 0.05/K, the next smallest P value 
with 0.05/(K-1), and so on until one of the ordered P values is larger 
than the relevant Holm’s cutoff. The Holm’s method keeps the overall 
type I error (false-positive rate) as low as that obtained by the Bonfer-
roni method but has better power (lower false-negative rate). In Figure 
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